Draft:Dr. Mohammad Arif

From Wikipedia, the free encyclopedia
  • Comment: Please remove all inline external links. There should be no links pointing to external resources until the footnotes in the 'References' section. DoubleGrazing (talk) 15:00, 19 May 2024 (UTC)
  • Comment: This is far too verbose, far too promotional, and far too sparsely referenced. DoubleGrazing (talk) 14:59, 19 May 2024 (UTC)
Mohammad Arif Hossain
Born
Gopalganj District, Bangladesh
CitizenshipJapanese
EducationOsaka University School of Medicine[1]
EmployerJCR pharmaceuticals ltd. [2]
Known forResearch on inherited metabolic diseases and Lysosomal storage disease
AwardsJSIMD Young Investigator Award, 2019 [3]

Dr. Mohammad Arif (有富 モハンマド) Hossain, also known as Dr. Hossain, is a distinguished research scientist who has made groundbreaking contributions to the field of lysosomal storage disorders (LSDs). His research has led to groundbreaking advances in diagnostic techniques and therapeutic approaches, including the development of chaperone therapies and novel biomarker-based methods.

Dr. Hossain's pioneering work has demonstrably improved clinical outcomes in Krabbe disease, galactosialidosis, and Fabry disease. He identified the prevalence of late-onset Krabbe disease in Japan, explored the potential of chaperone therapy with N-octyl-4- epi-β-valienamine (NOEV)for this condition, and linked the unfolded protein response (UPR) to disease progression. In galactosialidosis, his research demonstrated the potential of NOEV to enhance β-galactosidase activity, offering a promising new therapeutic avenue. He has also significantly advanced understanding of Fabry disease, uncovering the role of DNA methylation in disease severity in females and exploring the impact of enzyme replacement therapy on chronic leg ulcers.

His research extends beyond these specific diseases. He has generated patient-specific motor neurons from induced pluripotent stem cells (iPSCs) to study the neural cell dysfunction and apoptosis linked to metachromatic leukodystrophy (MLD), revealing critical insights into the pathological mechanisms of this condition. Additionally, his work has analyzed caregiver perspectives on the effects of pabinafusp alfa treatment in mucopolysaccharidosis II (MPS II), highlighting significant improvements in patients' quality of life.

Dr. Hossain’s dedication to improving patient outcomes extends to developing diagnostic tools. He has developed a cellular model using patient-specific iPSCs to study the neuropathological mechanisms of Niemann-Pick disease type C (NPC) and has innovated a highly accurate diagnostic method for NPC using a combination of biomarkers. He has also established a diagnostic approach utilizing 26:0 lysophosphatidylcholine quantification in dried blood spots for newborn screening of X-linked adrenoleukodystrophy (X-ALD) in Japan, and characterized PPT1 and TPP1 enzymes, paving the way for a newborn screening method for neuronal ceroid lipofuscinosis (NCL) types 1 and 2.

Dr. Hossain's extensive research on various LSDs and other Inborn errors of metabolism (IEM) has yielded valuable insights beyond these specific examples. He has demonstrated the therapeutic potential of genistein in mucolipidosis II (I-cell disease), described a rare case of adult-onset Pompe disease, reported the first case of Fazio-Londe syndrome from the Arabian Peninsula, and conducted a comprehensive study on IEMs in Saudi Arabia. These studies expand scientific knowledge and have practical implications for improving diagnostic accuracy and treatment approaches.

Scientific paper presentation at an international conference.
Scientific paper presentation at an international conference.

Dr. Hossain has authored more than 26 peer-reviewed articles.[1] in scientific journals. His pioneering efforts in uncovering the mechanisms and treatments for LSDs have earned him global recognition. He has been honored with numerous accolades, including the prestigious JSIMD Young Investigator Award[2] in 2019, the JHG Young Scientist Award in 2017[3], and the Kunihiko Suzuki Award[4] in 2017. His remarkable contributions to the field were acknowledged globally in 2020 when he was awarded the World Symposium Young Investigator Award[5]

Currently, Dr. Hossain dedicates his expertise as a medical advisor at JCR Pharmaceuticals Ltd. (since 2021) to focus on developing enzyme replacement therapy (ERT) for various LSDs. His commitment to this work holds significant promise for improving the lives of patients struggling with these debilitating conditions, a testament to his unwavering dedication to medical advancements.

Personal Life[edit]

Born into a large and loving family of 11 siblings in Bhatiapara, Kashiani, Gopalganj, Bangladesh, Dr. Hossain's upbringing fostered a strong emphasis on education. His family's commitment is further exemplified by his brother, the distinguished professor Dr. Md. Siddiqur Rahman of Bangladesh Agricultural University. Despite financial constraints, his parents, a small businessman and a housewife, instilled in him the value of education. It was his mother's dream to see him become a doctor, a dream that would shape his future. Driven by this dream and his determination, he excelled in his studies from a young age, paving the way for his remarkable career in medical research.

Dr. Hossain's academic journey was marked by excellence. He completed his primary and secondary education in his hometown before moving to Dhaka for his higher education. He attended Mirpur Bangla College for his higher secondary education and then went to Rajshahi Medical College to study medicine. After completing his MBBS, he practiced pediatrics and encountered numerous suspected LSD cases. The limitations in diagnosis fueled his desire for further research. He obtained a Ph.D. in Japan[6], where he made significant contributions to understanding LSDs, including discovering a novel therapeutic approach for Krabbe disease and Galactosialidosis.

Dr. Hossain's deep faith in one God is a cornerstone of his life and work. It instills in him a sense of humility and shapes his approach to pharmaceutical medicine. His belief in God's control and blessings motivates him to act with integrity, compassion, and a relentless pursuit of excellence and fills him with gratitude. This trust in something greater inspires trust and reliability in his audience.

While Dr. Hossain is dedicated to his scientific endeavors, he also enjoys exploring the universe's wonders. He is keenly interested in stargazing and the mysteries of the deep sea. Additionally, he enjoys traveling the world, immersing himself in diverse cultures, and broadening his horizons. When seeking relaxation, Dr. Hossain enjoys watching movies and appreciating the power of storytelling and entertainment.

While Dr. Hossain is dedicated to his scientific endeavors, he is also active outside of academics. He was the president of an organization called ADHUNIK during his medical career. This organization, founded by Professor Nurul Islam, a renowned physician and social activist in Bangladesh, aimed to raise awareness against smoking, particularly among young people. Dr. Hossain's commitment to public health extends beyond this role. During the COVID-19 pandemic, he regularly wrote newspaper articles to raise awareness about the crisis. He also actively participates in online discussions and television programs to promote child health and well-being.

Currently residing in Osaka, Japan, with his wife and three children, Dr. Hossain is a devoted family man. He cherishes spending quality time with his loved ones and finds a perfect balance between his dedication to research and his role as a husband and father.

Education[edit]

• FRCP, Royal College of Physicians and Surgeons, Glasgow, UK September 2021

• FRCPCH, Royal College of Pediatrics and Child Health, London, UK November 2020

• FRCP, Royal College of Physicians, Edinburgh, UK September 2020

• Clinical Fellowship, Osaka University Hospital, Japan March 2014

• Ph.D. (Medical Science), Osaka University Graduate School of Medicine, Japan March 2014

• MBBS, Rajshahi University, Rajshahi Medical College, Bangladesh April 2004

Professional Career[edit]

Dr. Hossain's medical career began with roles as a Medical Officer at the Islami Bank Medical College, Rajshahi (IBMCR), and a DCH (Diploma in Child Health) Physician at Rajshahi Medical College Hospital (RMCH). In December 2008, he joined IBMCR, Bangladesh, as a registered and specialist physician in the Department of Pediatrics. Just four months later, Dr. Hossain transitioned to Khwaja Yunus Ali Medical College, Bangladesh, as a consultant pediatrician and assistant professor in the Department of Pediatrics.

Dr. Hossain's research journey on LSDs began during his Ph.D. studies at Osaka University (October 2009 - March 2014). He focused on various lysosomal storage diseases (LSDs), including Krabbe disease, Galactosialidosis, and Mucolipidosis. His doctoral thesis specifically explored Krabbe disease, investigating its pathophysiology (how it develops) and leading to the discovery of promising new therapeutic approaches for Krabbe and Galactosialidosis.

Receiving FRCPH.
Receiving FRCPH.

Following graduation, Dr. Hossain spent two years (2014-2016) in Saudi Arabia working as a Specialist Pediatric Doctor and Co-investigator at the King Abdullah Specialized Children’s Hospital and Research Center. He also maintained a collaborative relationship with Professor Norio Sakai (at Osaka University, which allowed him to continue publishing research initiated during his Ph.D. studies.

In 2016, with Prof. Sakai's support, Dr. Hossain returned to Japan to join the Advanced Clinical Research Center as a laboratory chief scientist. There, he had the privilege of working alongside Prof. Yoshikatsu Eto, a leading figure and mentor in Japan's LSD research.

Prof. Eto's guidance opened doors for Dr. Hossain to explore a broader range of LSDs, including Fabry disease, Pompe disease, Metachromatic Leukodystrophy (MLD), Adrenoleukodystrophy (ALD), Neuronal Ceroid Lipofuscinosis (NCL), and Niemann-Pick disease type C (NPC). This diverse experience allowed him to make a significant contribution by uncovering a novel pathophysiological mechanism specifically affecting females with Fabry disease.

Since 2021, Dr. Hossain has been a medical advisor at JCR Pharmaceuticals Ltd. where their focus is on developing a next-generation enzyme replacement therapy (ERT) for various lysosomal storage diseases (LSDs). Current ERT treatments have limitations, as they are unable to reach the central nervous system (CNS) effectively and, therefore, cannot address neurocognitive impairment, a common symptom of many LSDs. JCR Pharmaceuticals is pioneering a new form of ERT (J-Brain Cargo®)[7] specifically designed to target both the CNS and somatic organs. This advancement has the potential to significantly improve the lives of LSD patients by not only addressing their physical symptoms but also helping to maintain average growth and development[8]. Dr. Hossain's expertise in LSDs allows them to play a vital role in this groundbreaking effort.

In addition to his research achievements, Dr. Hossain has been recognized as a valuable speaker and mentor in the field of LSDs. Notably, he has been invited as a guest speaker at the International Symposium on Data Science[9] in NAIST and served as a mentor at the WORLDSymposium[10], the largest international conference on LSDs.

Honors And Awards[edit]

  • Monbu-kagaku-shō also known as MEXT Scholarship Japanese Government Scholarship October 2009- March 2014
  • Young Investigator Award, 2011, Asian Congress for Inherited Metabolic Diseases (ACIMD), Tokyo, Japan
  • Young Investigator Award 2014 (Eto Prize), 56th Annual Meeting of the Japan Society of Inherited Metabolic Diseases and Asian Symposium of Inherited Metabolic Diseases, Sendai, Japan

Professional Affiliations And Licenses[edit]

Member, Society for the Study of Inborn Errors of Metabolism (SSIEM), Europe

Member, Japan Pediatrics Society

Member, Japanese Society of Human Genetics

Member, Japanese Society of Inherited Metabolic Diseases

Life Member, Bangladesh Pediatrics Association

Licenses[edit]

  1. Permanent medical license by Bangladesh Medical and Dental Council (BMDC): Reg No. A43074
  2. Permanent Medical license by Saudi Commission for Health Specialties (SCFHS): Reg No.  15-R-M-0015484

Publications And Books[edit]

  1. Nakamura K, Sakai N, Hossain MA, Eisengart JB, Yamamoto T, Tanizawa K, So S, Schmidt M, Sato Y. Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in Japan. Orphanet J Rare Dis. 2024 Mar 7;19(1):104. doi: 10.1186/s13023-024-03112-1. PubMed PMID: 38454486; PubMed Central PMCID: PMC10921713.
  2. Hossain MA, Hasegawa-Ogawa M, Manome Y, Igarashi M, Wu C, Suzuki K, Igarashi J, Iwamoto T, Okano HJ, Eto Y. Generation and characterization of motor neuron progenitors and motor neurons using metachromatic leukodystrophy-induced pluripotent stem cells. Mol Genet Metab Rep. 2022 Jun;31:100852. doi: 10.1016/j.ymgmr.2022.100852. eCollection 2022 Jun. PubMed PMID: 35782608; PubMed Central PMCID: PMC9248224.
  3. Saito R, Miyajima T, Iwamoto T, Wu C, Suzuki K, Hossain MA, Munakata M, Era T, Eto Y. A neuropathological cell model derived from Niemann-Pick disease type C patient-specific iPSCs shows disruption of the p62/SQSTM1-KEAP1-NRF2 Axis and impaired formation of neuronal networks. Mol Genet Metab Rep. 2021 Sep;28:100784. doi: 10.1016/j.ymgmr.2021.100784. eCollection 2021 Sep. PubMed PMID: 34377675; PubMed Central PMCID: PMC8327345.
  4. Wu C, Iwamoto T, Hossaina MA, Akiyama K, Igarashi J, Miyajima T, Eto Y. A combination of 7-ketocholesterol, lysosphingomyelin and bile acid-408 to diagnose Niemann-Pick disease type C using LC-MS/MS. PLoS ONE 2020, 15(9), e0238624.
  5. Hossain MA, Wu C, Yanagisawa H, Miyajima T, Akiyama K, Eto Y. Future clinical and biochemical predictions of Fabry disease in females by methylation studies of the GLA gene. Mol Genet Metab Rep. 2019, 20, 100497.
  6. Yanagisawa H, Hossain MA, Miyajima T, et al. Dysregulated DNA methylation of GLA gene was associated with dysfunction of autophagy. Mol Genet Metab 2019, 126(4), 460-465.
  7. Hossain MA, Miyajima T, Akiyama K, Eto Y. A case of adult-onset Pompe disease with cerebral stroke and left ventricular hypertrophy. J Stroke Cerebrovasc Dis 2018, 27(11), 3046-3052.
  8. Itagaki R, Endo M, Yanagisawa H, Hossain MA, Akiyama K, Yaginuma K, Miyajima T, Wu C, Iwamoto T, Igarashi J, Kobayashi Y, Tohyama J, Iwama K, Matsumoto N, Shintaku H, EtoY. Characteristics of PPT1 and TPP1 enzymes in neuronal ceroid lipofuscinosis (NCL) 1 and 2 by dried blood spots (DBS)and leukocytes and their application to newborn screening. Mol Genet Metab 2018, 124(1), 64-70.
  9. Irahara-Miyana K, Otomo T, Kondo H, Hossain MA, Ozono K, Sakai N. Unfolded protein response is activated in Krabbe disease in a manner dependent on the mutation type. JHG 2018, 63(6), 699-706.
  10. *Okada J, *Hossain MA, Wu C, Miyajima T, Yanagisawa H, Akiyama K, Eto Y. Ten-year-long enzyme replacement therapy shows a poor effect in alleviating giant leg ulcers in a male with Fabry disease. Mol Genet Metab Rep 2017, 14, 68-72. *Equal contribution.
  11. Hossain MA, Yanagisawa H, Miyajima T, Wu C, Takamura A, Akiyama K, Itagaki R, Eto K, Iwamoto T, Yokoi T, Kurosawa K, Numabe H, Eto Y. The severe clinical phenotype for a heterozygous Fabry female patient correlates to the methylation of non-mutated allele associated with chromosome 10q26 deletion syndrome. Mol Genet Metab 2017, 120 (3), 173–179.
  12. Wu C, Iwamoto T, Igarashi J, Miyajima T, Hossaina MA, Yanagisawaa H, Akiyama K, Shintaku H, Eto Y. Application of a diagnostic methodology by quantification of 26:0 lysophosphatidylcholine in dried blood spots for Japanese newborn screening of X-linked adrenoleukodystrophy. Mol Genet Metab Rep 2017, 12, 115–118.
  13. Hossain MA, Obaid A, Rifai M, Alem H, Hazwani T, Shehri AA, Alfadhel M, Eto Y, Eyaid W. An early onset of Fazio–Londe Syndrome; first case report from Arab peninsula. Hum Genome Var 2017, 4, 17018.
  14. Alfadhel M, Benmeakel M, Hossain MA, Mutairi FA, Othaim AA, Alfares AA, Balwi MA, Alzaben A, Eyaid W. Thirteen year retrospective review of the spectrum of inborn errors of metabolism presenting in a tertiary center in Saudi Arabia. Orphanet Journal of Rare Diseases 2016, 11 (1),126.
  15. Hossain MA, Higaki K, Shinpo M, Nanba E, Suzuki Y, Ozono K, Sakai N. Chemical chaperone treatment for galactosialidosis: Effect of NOEV on β-galactosidase activities in fibroblasts. BRADEV 2016, 38 (2), 175–80.
  16. Hossain MA, Higaki K, Saito S, Ohno K, Sakuraba H, Nanba E, Suzuki Y, Ozono K, Sakai N. Chaperone therapy for Krabbe disease: potential for late-onset GALC mutations. JHG 2015, 60 (9), 539–45.
  17. Hossain MA, Otomo T, Seiji Saito, Kazuki Ohno, Hitoshi Sakuraba, Hamada Y, Ozono K, Sakai N. Late-onset Krabbe disease is predominant in Japan and its mutant precursor protein undergoes more effective processing than the infantile onset form. GENE 2014, 534 (2), 144–54.
  18. Otomo T, Hossain MA, Ozono K, Sakai N. Genistein reduces heparan sulfate accumulation in human mucolipidosis II skin fibroblasts. Mol Genet Metab 2012, 105(2), 266-69.
  19. Kardas F, Uzak AS, Hossain MA, Sakai N, Canpolat M, Yıkılmaz A. A Novel Homozygous GALC Mutation: Very Early Onset and Rapidly Progressive Krabbe Disease. GENE 2013, 517 (1), 125- 27.
  20. Tokushige SI, Sonoo T, Maekawa R, Shirota Y, Hanajima R, Terao Y, Matsumoto H, Hossain MA, Sakai N, Shiio Y. Isolated pyramidal tract impairment in the central nervous system of adult-onset Krabbe disease with novel mutations in the GALC gene. Brain Dev 2013, 35 (6), 579-81.
  21. Rahman MS, Nagai Y, Popiel HA, Fujikake N, Okamoto Y, Ahmed MU, Islam MA, Islam MT, Ahmed S, Rahman KM, Uddin MJ, Dey SK, Ahmed Q, Hossain MA, Jahan N, Toda T. Genetic testing for Huntington’s disease in Parkinsonism. Mymensingh Med J 2010, 19(4), 510-14.
  22. Rahman AKMA, Begum N, Nooruddin M, Rahman MS, Hossain MA, Song HJ. Prevalence and risk factors of helminth infections in cattle of Bangladesh. Korean Journal of Veterinary Service 2009, 32 (3), 265-73.
  23. Uddin MJ, Rahman MS, Akter SH, Hossain MA, Islam MT, Islam MA, Park JH, Song HJ. Seroprevalence of brucellosis in small ruminants in selected area of Bangladesh. Korean Journal of Veterinary Service 2007,31 (4), 511-25.
  24. Uddin JM, Rahman MS, Hossain MA, Akter SH, Majumder S, Park JH, Song HJ. Relation between brucellosis and husbandry practices in goats in Bangladesh. Korean Journal of Veterinary Service 2007, 30 (2), 259-67.
  25. Rahman AKMA, Nooruddin M, Hossain MM, Rahman MS, Hossain MA, Song HJ. Pulmonary Diseases in Slaughtered Cattle 4. Pathology of Pulmonary Lesions. Korean Journal of Veterinary Service 2006, 29 (4), 483-87.
  26. Rahman MS, Uddin MJ, Park JH, Chae JS, Rahman MB, Islam MA. A short history of brucellosis: special emphasis in Bangladesh. Bangl. J. Vet. Med 2006, 4 (1), 01–06.

Books[edit]

Dr. Hossain has authored Chapter 6 of the book Krabbe Disease. Inherited metabolic diseases handbook (先天代謝異常ハンドブック). Published by Nakayama Shoten Co. Ltd. Volume 1, Issue 1 (2013).  With Sakai N.

References[edit]

  1. ^ "My Bibliography - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2024-05-19.
  2. ^ "過去の受賞者：一般社団法人 日本先天代謝異常学会". jsimd.net. Retrieved 2024-05-19.
  3. ^ Matsumoto, Naomichi (December 2017). "The 2017 JHG Young Scientist Award". Journal of Human Genetics. 62 (12): 1007. doi:10.1038/jhg.2017.89. ISSN 1435-232X.
  4. ^ "研究会賞（鈴木邦彦賞）Award – 日本ライソゾーム病研究会" (in Japanese). Retrieved 2024-05-19.
  5. ^ WORLDSymposium (2020-02-10). "WORLDSymposium 2020 Young Investigator Awards". WORLDSymposium. Retrieved 2024-05-19.
  6. ^ Hossain, Mohammad Arif; ホセイン, モハンマド アリフ (2014-03-25). "Late-onset Krabbe disease is predominant in Japan and its mutant precursor protein undergoes more effective processing than the infantile-onset form". hdl:11094/34215. {{cite journal}}: Cite journal requires |journal= (help)
  7. ^ "R&D / Production | JCR Pharmaceuticals Co., Ltd". www.jcrpharm.co.jp. Retrieved 2024-05-19.
  8. ^ Tomita, Kazuyoshi; Okamoto, Shungo; Seto, Toshiyuki; Hamazaki, Takashi; So, Sairei; Yamamoto, Tatsuyoshi; Tanizawa, Kazunori; Sonoda, Hiroyuki; Sato, Yuji (November 2021). "Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report". JIMD Reports. 62 (1): 9–14. doi:10.1002/jmd2.12239. ISSN 2192-8304. PMC 8574176. PMID 34765392.
  9. ^ "2nd NAIST International Symposium on Data Science". naist-datascience-symp2022.github.io. Retrieved 2024-05-19.
  10. ^ "Speed Mentoring Mentee Sign up". WORLDSymposium. Retrieved 2024-05-19.

External links[edit]

  1. News about Dr. Hossain's becoming the best young scientist of Japan in English, Bangladesh's Arif selected as best young scientist of Japan
  2. News about Dr. Hossain's becoming the best young scientist of Japan in Bangla, জাপানের সেরা তরুণ বিজ্ঞানী বাংলাদেশের আরিফ হোসেন
  3. Interview of Dr. Hossain in Bangla, আরিফের রেকর্ড ভাঙার গল্প,
  4. Interview of Dr. Hossain in Bangla, দেশের মানুষের জন্য কাজ করতে চাই,
  5. Dr. Hossain's news paper article about children's mental wellbeing during the Pandemic in Bangla করোনায় শিশু-কিশোরদের মানসিক অবসাদ যেভাবে দূর করবেন
  6. Dr. Hossain's news paper article on common misconceptions about Covid-19 in Banglaকরোনাভাইরাসের চিকিৎসা ও কিছু বিভ্রান্তি
  7. Dr. Hossain's news paper article on possibilities of potential drugs of Covid-19 in Bangla, করোনা প্রতিরোধে নাকের স্প্রে ভ্যাকসিন নিয়ে নতুন সম্ভাবনা
  8. Dr. Hossain's news paper article on potential of vitamin-D for treating Covid-19 in Bangla,ভিটামিন-ডি কীভাবে করোনাভাইরাস সংক্রমণ ঠেকাবে?
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Dr._Mohammad_Arif&oldid=1224691003"